# Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

> **NCT03706547** · PHASE1 · UNKNOWN · sponsor: **Peng Liu** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma Progression

## Interventions

- **BIOLOGICAL:** anti-CD19/BCMA CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03706547
- **Lead sponsor:** Peng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-30
- **Primary completion:** 2020-07
- **Final completion:** 2021-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-10-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706547, "Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03706547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*